High-level set the tone requires the normalization of drug collection institutionalization of collection and harvesting over the years!

Recently, the National Organization for the Central Procurement and Use of Drugs Joint Procurement Office issued an announcement, the fourth batch of work will begin, involving 45 varieties.
Joint Procurement Office will receive the filings on 3 February.
executive meeting of the State Council held on January 15th called for the three-doctor association to be adhered to in accordance with the deployment of medical reform and to promote the institutionalization of the normalization of drug collection.
In accordance with the basic and clinical principles, focus on the basic medical insurance drug catalog of large quantities of drugs, high procurement amount of drugs into the procurement scope, and gradually cover the domestic market clinically necessary, reliable quality of various types of drugs and consumables.
means that the pace of drug collection is getting faster and faster, more and more drugs and consumables are included, drug collection is becoming normal and institutionalized.
Premier Li Keqiang presided over an executive meeting of the State Council on January 15 to strengthen the living security of the people affected by the epidemic and the low-security groups during the "two sections", and to further promote the reform of drug centralized belt procurement to reduce the burden of medical treatment by normalizing institutionalized measures. the
meeting pointed out that in order to gradually solve the problem of expensive medical care, in recent years, the state has promoted the procurement and use of centralized drug volume major reforms, as of the end of last year has carried out three batches of collection, covering the average price of drugs reduced by 54%, saving more than 53 billion yuan a year, benefiting hundreds of millions of patients.
will soon carry out the fourth batch of collection, and expand the range of high-value medical supplies collection.
meeting called for the deployment of medical reform, adhere to the "three-doctor linkage" to promote the normalization of drug collection and institutionalization.
First, in accordance with the basic and clinical principles, focus on the basic medical insurance drug catalog of large quantities, high procurement amount of drugs into the procurement scope, and gradually cover the domestic market clinically necessary, reliable quality of various types of drugs and consumables.
public medical institutions should participate in the collection.
study made special arrangements for the procurement of "orphan drugs" for the treatment of rare diseases.
is that qualified generic drugs, original research drugs and referentic preparations are all in the general name to participate in the collection, through quality and price fair competition to produce selected enterprises and drugs, consumables.
medical institutions should ensure that the priority is given to the use of selected medicines and that procurement volume is maximized as needed.
selected enterprises to ensure that price reduction does not reduce quality, does not reduce efficacy, to ensure supply.
strengthen the production, circulation and use of selected drugs and consumables throughout the chain supervision.
This is to collect and reduce the burden on patients at the same time, taking into account the reasonable profits of enterprises, promote the pharmaceutical and consumables industry in the competition to improve concentration, promote product innovation and upgrading, to save medical insurance costs in accordance with the provisions to give medical institutions residual incentives, and strive to make this reform to achieve patients and enterprises, medical institutions have benefited.
In late July 2020, the General Office of the State Council issued the Notice of the General Office of the State Council on the Issue of Key Tasks for Deepening the Reform of the Medical and Health System in the Second Half of 2020, which explicitly called for "guiding the local implementation of the procurement, distribution and use policies for selected medicines and high-value medical supplies."
to formulate policy documents to reform and improve drug procurement mechanisms."
A month later, the "National Health Insurance Administration on the establishment of pharmaceutical prices and credit evaluation system guidance" (Medical Insurance Issue (2020) No. 34) of the measures of this document, equivalent to a series of early and drug collection and collection of new regulations supporting a series of basic security work, for the drug collection of new regulations "launched" to create a more favorable "environment."
, "drug prices are inflated" "with gold sales" and other problems plagued the pharmaceutical industry.
how to play the macro-control and regulatory role of the "tangible hand" while returning drug pricing power to the market? At present, China makes full use of the market mechanism of "price-for-volume" by means of national organization of drug collection and collection, and turns from passive buying to active bargaining.
It can be foreseen that the normal institutionalization of drug collection will enable more drugs and medical supplies to be included in the scope of collection, in the benefit of hundreds of millions of patients at the same time, by cutting off the circulation of medicine at inflated prices, forcing the pharmaceutical industry and medical system reform.
Drug collection standardizes the drug circulation process, frees pharmaceutical companies from the disorderly competition of "selling with gold" in the past, improves the quality of drugs and embarks on the road of high-quality development;